Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + abiraterone acetate + prednisone versus placebo + abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer
MOH_2019-03-17_006026Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Janssen Pharmaceutical. Started Feb 2019; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2019-03-17_006026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-17_006026.